Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver

Toxicology and Applied Pharmacology

Volumn 226, Issue 3, 2008, Pages 271-284

  Lee, Min Ho ^a   Kim, Mingoo ^b,f   Lee, Byung Hoon ^a,f   Kim, Ju Han ^b,f   Kang, Kyung Sun ^c,f   Kim, Hyung Lae ^d,f   Yoon, Byung Il ^e,f   Chung, Heekyoung ^f   Kong, Gu ^f   Lee, Mi Ock ^a,f  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Ewha Womans University   (South Korea)

^e Kangwon National University   (South Korea)

^f Hanyang University   (South Korea)

Author keywords

Fatty liver; Microarray analysis; Subchronic exposure; Toxicogenomics; Valproic acid

Indexed keywords

CHOLESTEROL; FATTY ACID; LIPID; STEROID; TRIACYLGLYCEROL; VALPROIC ACID;

ADPN GENE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYP4A14 GENE; DRUG EFFECT; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENE; GENE EXPRESSION PROFILING; LIPID METABOLISM; LIVER METABOLISM; LIVER TOXICITY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS, TOXIC; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED ICR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TRIGLYCERIDES; VALPROIC ACID;

MUS;

EID: 38649097885     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.09.014     Document Type: Article

References (77)

1. Armutcu F., Ozerol E., Gurel A., Kanter M., Vural H., Yakinci C., and Akyol O. Effect of long-term therapy with sodium valproate on nail and serum trace element status in epileptic children. Biol. Trace Elem. Res. 102 (2004) 1-10
2. Bamberger A.M., Milde-Langosch K., Rossing E., Goemann C., and Loning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J. Cancer Res. Clin. Oncol. 127 (2001) 545-550
3. Becker C.M., and Harris R.A. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch. Biochem. Biophys. 223 (1983) 381-392
4. Bittigau P., Sifringer M., Genz K., Reith E., Pospischil D., Govindarajalu S., Dzietko M., Pesditschek S., Mai I., Dikranian K., Olney J.W., and Ikonomidou C. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15089-15094
5. Blaheta R.A., and Cinatl Jr. J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 22 (2002) 492-511
6. Blaheta R.A., Michaelis M., Driever P.H., and Cinatl Jr. J. Evolvinganticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 25 (2005) 383-397
7. Bolstad B.M., Irizarry R.A., Astrand M., and Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 22 (2003) 185-193
8. Bosetti F., Bell J.M., and Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res. Bull. 65 (2005) 331-338
9. Boverhof D.R., Burgoon L.D., Tashiro C., Chittim B., Harkema J.R., Jump D.B., and Zacharewski T.R. Temporal and dose-dependent hepatic gene expression patterns in mice provide new insights into TCDD-mediated hepatotoxicity. Toxicol. Sci. 85 (2005) 1048-1063
10. Bowden C.L. Valproate. Bipolar Disord. 5 (2003) 189-202
11. Chen J., Yu L., Li D., Gao Q., Wang J., Huang X., Bi G., Wu H., and Zhao S. Human CRYL1, a novel enzyme-crystallin overexpressed in liver and kidney and downregulated in 58% of liver cancer tissues from 60 Chinese patients, and four new homologs from other mammalians. Gene 302 (2003) 103-113
12. Chung H., Kim H.J., Jang K.S., Kim M., Yang J., Kang K.S., Kim H.L., Yoon B.I., Lee M.O., Lee B.H., Kim J.H., Lee Y.S., and Kong G. Comprehensive analysis of differential gene expression profiles on d-galactosamine-induced acute mouse liver injury and regeneration. Toxicology 227 (2006) 136-144
13. Chung H., Kim H.J., Jang K.S., Kim M., Yang J., Kim J.H., Lee Y.S., and Kong G. Comprehensive analysis of differential gene expression profiles on diclofenac-induced acute mouse liver injury and recovery. Toxicol. Lett. 166 (2006) 77-87
14. Cotariu D., and Zaidman J.L. Valproic acid and the liver. Clin. Chem. 34 (1988) 890-897
15. Davis R., Peters D.H., and McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 (1994) 332-372
16. Death A.K., McGrath K.C., and Handelsman D.J. Valproate is an anti-androgen and anti-progestin. Steroids 70 (2005) 946-953
17. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
18. Eadie M.J., Hooper W.D., and Dickinson R.G. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. Adverse Drug Exp. 3 (1988) 85-106
19. Eaton D.L., and Bammler T.K. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol. Sci. 49 (1999) 156-164
20. Fromenty B., and Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67 1 (1995) 101-154
21. Gunther E.C., Stone D.J., Gerwien R.W., Bento P., and Heyes M.P. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9608-9613
22. Hayes J.D., Flanagan J.U., and Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 51-88
23. Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., Spiegelman B., and Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413 (2001) 179-183
24. Hjelm M., Oberholzer V., Seakins J., Thomas S., and Kay J.D. Valproate-induced inhibition of urea synthesis and hyperammonaemia in healthy subjects. Lancet 2 (1986) 859
25. Ho Sui S.J., Mortimer J.R., Arenillas D.J., Brumm J., Walsh C.J., Kennedy B.P., and Wasserman W.W. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 33 (2005) 3154-3164
26. Huber W., von Heydebreck A., Sultmann H., Poustka A., and Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (2002) 96-104
27. Jetten A.M. Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr. Drug Targets Inflamm. Allergy 3 (2004) 395-412
28. Jimenez-Rodriguezvila M., Caro-Paton A., Duenas-Laita A., Conde M., Coca M.C., Martin-Lorente J.L., Velasco A., and Maranon A. Histological, ultrastructural and mitochondrial oxidative phosphorylation studies in liver of rats chronically treated with oral valproic acid. J. Hepatol. 1 (1985) 453-465
29. Jogl G., Hsiao Y.S., and Tong L. Structure and function of carnitine acyltransferases. Ann. N. Y. Acad. Sci. 1033 (2004) 17-29
30. Jolly R.A., Goldstein K.M., Wei T., Gao H., Chen P., Huang S., Colet J.M., Ryan T.P., Thomas C.E., and Estrem S.T. Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants. Physiol. Genomics 22 (2005) 346-355
31. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Safety 24 (2001) 483-490
32. Kassahun K., and Abbott F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid. Drug Metab. Dispos. 21 (1993) 1098-1106
33. Kesterson J.W., Granneman G.R., and Machinist J.M. The hepatotoxicity of valproic acid and its metabolites in rats: I. Toxicologic, biochemical and histopathologic studies. Hepatology 4 (1984) 1143-1152
34. Kroetz D.L., Yook P., Costet P., Bianchi P., and Pineau T. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J. Biol. Chem. 273 (1998) 31581-31589
35. Kultima K., Nystrom A.M., Scholz B., Gustafson A.L., Dencker L., and Stigson M. Valproic acid tratogenicity: a toxicogenomics approach. Environ. Health Perspect. 112 (2004) 1225-1235
36. Lagace D.C., and Nachtigal M.W. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J. Biol. Chem. 279 (2004) 18851-18860
37. Lampen A., Siehler S., Ellerbeck U., Gottlicher M., and Nau H. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol. Appl. Pharmacol. 160 (1999) 238-249
38. Langer S., Singer C.F., Hudelist G., Dampier B., Kaserer K., Vinatzer U., Pehamberger H., Zielinski C., Kubista E., and Schreibner M. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur. J. Gynaecol. Oncol. 27 (2006) 345-352
39. Lee W.M. Review article: drug-induced hepatotoxicity. Aliment. Pharmacol. Ther. 7 (1993) 477-485
40. Lee E.J., Jeong I.H., Kim H.N., Chung H., Kong G., Kang K.S., Yoon B.I., Lee B.H., Lee M.O., Kim J.H., and Kim H.L. Gene expression alalysis of phenylbutazone-induced liver damage in mice. J. Toxicol. Pub. Health 22 (2006) 87-93
41. Lee M.H., Hong I., Kim M., Lee B.H., Kim J.H., Kang K.S., Kim H.L., Yoon B.I., Chung H., Kong G., and Lee M.O. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol. Appl. Pharmacol. 220 (2007) 45-59
42. Lewis J.H., Zimmerman H.J., Garrett C.T., and Rosenberg E. Valproateinduced hepatic steatogenesis in rats. Hepatology 2 (1982) 870-873
43. Liu J.S., Park E.A., Gurney A.L., Roesler W.J., and Hanson R.W. Cyclic AMP induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription is mediated by multiple promoter elements. J. Biol. Chem. 266 (1991) 19095-19102
44. Loscher W. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J. Pharmacol. Exp. Ther. 204 (1978) 255-261
45. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58 (1999) 31-59
46. Lu Z., Lam K.S., Wang N., Xu X., Cortes M., and Andersen B. LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene 25 (2006) 2920-2930
47. May R.B., and Sunder T.R. Hematologic manifestations of long-term valproate therapy. Epilepsia 34 (1993) 1098-1101
48. Mi H., Lazareva-Ulitsky B., Loo R., Kejariwal A., Vandergriff J., Rabkin S., Guo N., Muruganujan A., Doremieux O., Campbell M.J., Kitano H., and Thomas P.D. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 33 (2005) 284-288
49. Ogata H., Goto S., Sato K., Fujibuchi W., Bono H., and Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 27 (1999) 29-34
50. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
51. Pessayre D., and Larrey D. Acute and chronic drug-induced hepatitis. Bailliere's Clin. Gastroenterol. 2 (1988) 385-422
52. Phillips A., Bullock T., and Plant N. Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO. Toxicology 192 (2003) 219-227
53. Ponchaut S., van Hoof F., and Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem. Pharmacol. 43 (1992) 2435-2442
54. Raspe E., Duez H., Gervois P., Fievet C., Fruchart J.C., Besnard S., Mariani J., Tedgui A., and Staels B. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J. Biol. Chem. 276 (2001) 2865-2871
55. Reddy J.K. Nonalcoholic steatosis and steatohepatitis: III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J. Physiol.: Gasterointest. Liver Physiol. 281 (2001) 1333-1339
56. Richards V.E., Chau B., White M.R., and McQueen C.A. Hepatic gene expression and lipid homeostasis in C57BL/6 mice exposed to hydrazine or acetylhydrazine. Toxicol. Sci. 82 (2004) 318-332
57. Rogiers V., Vandenberghe Y., and Vercruysse A. Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes. Xenobiotica 15 (1985) 759-765
58. Roma-Giannikou E., Syriopoulou V., Kairis M., Pangali A., Sarafidou J., and Constantopoulos A. In vivo effect of sodium valproate on mouse liver. Cell. Mol. Life Sci. 56 (1999) 363-369
59. Rumbach L., Warter J.M., Rendon A., Marescaux C., Micheletti G., and Waksman A. Inhibition of oxidative phosphorylation in hepatic and cerebral mitochondria of sodium valproate-treated rats. J. Neurol. Sci. 61 (1983) 417-423
60. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., Sturn A., Snuffin M., Rezantsev A., Popov D., Ryltsov A., Kostukovich E., Borisovsky I., Liu Z., Vinsavich A., Trush V., and Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34 (2003) 374-378
61. Schmidt D. Adverse effects of valproate. Epilepsia 25 (1984) 44-49
62. Schnackenberg L.K., Jones R.C., Thyparambil S., Taylor J.T., Han T., Tong W., Hansen D.K., Fuscoe J.C., Edmondson R.D., Beger R.D., and Dragan Y.P. An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS 10 (2006) 1-14
63. Shen W.T., Wong T.S., Chung W.Y., Wong M.G., Kebebew E., Duh Q.Y., and Clark O.H. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 138 (2005) 979-984
64. Steinley D. K-means clustering: a half-century synthesis. Br. J. Math. Stat. Psychol. 59 (2006) 1-34
65. Tang Y., Glauser T.A., Gilbert D.L., Hershey A.D., Privitera M.D., Ficker D.M., Szaflarski J.P., and Sharp F.R. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol., Scand. 109 (2004) 159-168
66. Teusink B., Mensenkamp A.R., van der Boom H., Kuipers F., van Dijk K.W., and Havekes L.M. Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor. J. Biol. Chem. 276 (2001) 40693-40697
67. Tong V., Teng X.W., Chang T.K., and Abbott F.S. Valproic acid: I. Time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol. Sci. 86 (2005) 427-435
68. Troyanskaya O., Cantor M., Sherlock G., Brown P., Hastie T., Tibshirani R., Botstein D., and Altman R.B. Missing value estimation methods for DNA microarrays. Bioinformatics 17 (2001) 520-525
69. Twisk J., Gillian-Daniel D.L., Tebon A., Wang L., Barrett P.H., and Attie A.D. The role of the LDL receptor in apolipoprotein B secretion. J. Clin. 105 (2000) 521-532
70. van der Leij F.R., Huijkman N.C., Boomsma C., Kuipers J.R., and Bartelds B. Genomics of the human carnitine acyltransferase genes. Mol. Genet. Metab. 71 (2000) 139-153
71. Visvader J.E., Venter D., Hahm K., Santamaria M., Sum E.Y., O'Reilly L., White D., Williams R., Armes J., and Lindeman G.J. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14452-14457
72. Vrana K.E., Freeman W.M., and Aschner M. Use of microarray technologies in toxicology research. Neurotoxicology 24 (2003) 321-332
73. Wang J.F., Azzam J.E., and Young L.T. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 116 (2003) 485-489
74. Wolfgang M.J., Kurama T., Dai Y., Suwa A., Asaumi M., Matsumoto S., Cha S.H., Shimokawa T., and Lane M.D. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7282-7287
75. Xia Q., Sung J., Chowdhury W., Chen C.L., Hoti N., Shabbeer S., Carducci M., and Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 66 (2006) 7237-7244
76. Yin H.Q., Kim M., Kim J.H., Kong G., Lee M.O., Kang K.S., Yoon B.I., Kim H.L., and Lee B.H. Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. Toxicol. Sci. 94 (2006) 206-216
77. Zimmerman H.J. Hepatotoxicity. Dis. Mon. 39 (1993) 675-787